BRNS Stock Analysis: Buy, Sell, or Hold?
BRNS - Barinthus Biotherapeutics plc American Depositary Shares
$0.70
0.04 (6.18%)
▲
5d:
+0.14%
30d:
+10.36%
90d:
+16.8%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When BRNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BRNS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BRNS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BRNS is currently trading at $0.70, which is considered extended relative to its 30-day fair value range of $0.64 to $0.70.
Technical Outlook: Technically, BRNS is in a downtrend. The price is approaching resistance at $0.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+684.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BRNS is in a downtrend. The price is approaching resistance at $0.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+684.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.64 -
$0.70
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
56.3%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.2%)
- BULLISH: Trading 684.8% below Wall St target ($5.50)
Trading Range Analysis
30-Day Trading Range
$0.64 -
$0.70
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.64
Resistance Level
$0.72
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.61
Wall Street Target
$5.50
(+684.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 03, 2026 8:52 PM ET
Data refreshes hourly during market hours. Next update: 9:52 PM
Data refreshes hourly during market hours. Next update: 9:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BRNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 52 HOLD |
